Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale. SIGNIFICANCE: In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli-specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies. This article is highlighted in the In This Issue feature, p. 2221.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
2 retracted
Dubourg, G., Morand, A., Mekhalif, F., Godefroy, R., Corthier, A., Yacouba, A., Diakite, A., Cornu, F., Cresci, M., Brahimi, S., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.513305 · Cited by 66
RetractedRETRACTED ARTICLE: Tobacco-smoking-related prevalence of methanogens in the oral fluid microbiota
Grine, G., Terrer, E., Boualam, M. A., Aboudharam, G., Chaudet, H., Ruimy, R., & Drancourt, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27372-7 · Cited by 57
RetractedThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationUrinary tract infections: epidemiology, mechanisms of infection and treatment options
Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3432 · Cited by 4,213
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Self-citationPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E.-A. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.047 · Cited by 2,303
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Self-citationDefining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Seng, P., Drancourt, M., Gouriet, F., La Scola, B., Fournier, P., Rolain, J. M., & Raoult, D. (2009) · Clinical Infectious Diseases · doi:10.1086/600885 · Cited by 1,983
B cells are associated with survival and immunotherapy response in sarcoma
Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1906-8 · Cited by 1,942
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002788 · Cited by 1,493
Self-citationUpdated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
Alfred Witjes, J., Lebret, T., Compérat, E. M., Cowan, N. C., De Santis, M., Bruins, H. M., Hernández, V., Espinós, E. L., Dunn, J., Rouanne, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.06.020 · Cited by 1,476
Self-citationPowles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Self-citationPushalkar, S., Hundeyin, M., Daley, D., Zambirinis, C. P., Kurz, E., Mishra, A., Mohan, N., Aykut, B., Usyk, M., Torres, L. E., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1134 · Cited by 1,400
Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,333
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
Self-citationAdjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034442 · Cited by 1,065
Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer
Fu, A., Yao, B., Dong, T., Chen, Y., Yao, J., Liu, Y., Li, H., Bai, H., Liu, X., Zhang, Y., et al. (2022) · Cell · doi:10.1016/j.cell.2022.02.027 · Cited by 981
Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897
Self-citationMulvey, M. A., Schilling, J. D., & Hultgren, S. J. (2001) · Infection and Immunity · doi:10.1128/iai.69.7.4572-4579.2001 · Cited by 849
Meylan, M., Petitprez, F., Becht, E., Bougoüin, A., Pupier, G., Calvez, A., Giglioli, I., Verkarre, V., Lacroix, G., Verneau, J., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.02.001 · Cited by 831
Patnaik, A., Kang, S. P., Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., Drengler, R., Chen, C., Smith, L., Espino, G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2607 · Cited by 807
Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741
Powles, T., Kockx, M., Rodriguez-Vida, A., Duran, I., Crabb, S. J., Van Der Heijden, M. S., Szabados, B., Pous, A. F., Gravis, G., Herranz, U. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0628-7 · Cited by 591
Self-citationAkkermansia muciniphila induces intestinal adaptive immune responses during homeostasis
Ansaldo, E., Slayden, L. C., Ching, K. L., Koch, M. A., Wolf, N. K., Plichta, D. R., Brown, E. M., Graham, D. B., Xavier, R. J., Moon, J. J., et al. (2019) · Science · doi:10.1126/science.aaw7479 · Cited by 566
Balar, A. V., Kamat, A. M., Kulkarni, G. S., Uchio, E. M., Boormans, J. L., Roumiguié, M., Krieger, L. E. M., Singer, E. A., Bajorin, D. F., Grivas, P., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00147-9 · Cited by 565
Schalper, K. A., Carleton, M., Zhou, M., Chen, T., Feng, Y., Huang, S.-P., Walsh, A. M., Baxi, V., Pandya, D., Baradet, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0856-x · Cited by 548
c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont
Xu, M., Pokrovskii, M., Ding, Y., Yi, R., Au, C., Harrison, O. J., Galan, C., Belkaid, Y., Bonneau, R., & Littman, D. R. (2018) · Nature · doi:10.1038/nature25500 · Cited by 498
Cui, C., Wang, J., Fagerberg, E., Chen, P.-M., Connolly, K. A., Damo, M., Cheung, J. F., Mao, T., Askari, A. S., Chen, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.007 · Cited by 479
Hollern, D. P., Xu, N., Thennavan, A., Glodowski, C., Garcia-Recio, S., Mott, K. R., He, X., Garay, J. P., Carey-Ewend, K., Marron, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.028 · Cited by 478
Identification of bacteria-derived HLA-bound peptides in melanoma
Kalaora, S., Nagler, A., Nejman, D., Alon, M., Barbolin, C., Barnea, E., Ketelaars, S. L. C., Cheng, K., Vervier, K., Shental, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03368-8 · Cited by 457
PD-1 Blockade Expands Intratumoral Memory T Cells
Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0210 · Cited by 405
van Dijk, N., Gil-Jimenez, A., Silina, K., Hendricksen, K., Smit, L. A., de Feijter, J. M., van Montfoort, M. L., van Rooijen, C., Peters, D., Broeks, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1085-z · Cited by 404
Graham, L., & Orenstein, J. M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.304 · Cited by 399
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Voabil, P., de Bruijn, M., Roelofsen, L. M., Hendriks, S. H., Brokamp, S., van den Braber, M., Broeks, A., Sanders, J., Herzig, P., Zippelius, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01398-3 · Cited by 380
Sautès-Fridman, C., Lawand, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Dieu-Nosjean, M.-C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00407 · Cited by 379
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer
Gu-Trantien, C., Migliori, E., Buisseret, L., de Wind, A., Brohée, S., Garaud, S., Noël, G., Dang Chi, V. L., Lodewyckx, J.-N., Naveaux, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91487 · Cited by 368
Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy
Wang, M., Yao, L., Cheng, M., Cai, D., Martinek, J., Pan, C., Shi, W., Ma, A., de Vere White, R. W., Airhart, S., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201700740r · Cited by 339
Lower Airway Dysbiosis Affects Lung Cancer Progression
Tsay, J.-C. J., Wu, B. G., Sulaiman, I., Gershner, K., Schluger, R., Li, Y., Yie, T.-A., Meyn, P., Olsen, E., Perez, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0263 · Cited by 322
Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1086-y · Cited by 318
Overacre-Delgoffe, A. E., Bumgarner, H. J., Cillo, A. R., Burr, A. H. P., Tometich, J. T., Bhattacharjee, A., Bruno, T. C., Vignali, D. A. A., & Hand, T. W. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.003 · Cited by 318
Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
Scapin, G., Yang, X., Prosise, W. W., McCoy, M., Reichert, P., Johnston, J. M., Kashi, R. S., & Strickland, C. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3129 · Cited by 259
IgA transcytosis and antigen recognition govern ovarian cancer immunity
Biswas, S., Mandal, G., Payne, K. K., Anadon, C. M., Gatenbee, C. D., Chaurio, R. A., Costich, T. L., Moran, C., Harro, C. M., Rigolizzo, K. E., et al. (2021) · Nature · doi:10.1038/s41586-020-03144-0 · Cited by 248
Roberti, M. P., Yonekura, S., Duong, C. P. M., Picard, M., Ferrere, G., Tidjani Alou, M., Rauber, C., Iebba, V., Lehmann, C. H. K., Amon, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0882-8 · Cited by 208
Self-citationAbraham, S. N., Sun, D., Dale, J. B., & Beachey, E. H. (1988) · Nature · doi:10.1038/336682a0 · Cited by 197
Chaurio, R. A., Anadon, C. M., Lee Costich, T., Payne, K. K., Biswas, S., Harro, C. M., Moran, C., Ortiz, A. C., Cortina, C., Rigolizzo, K. E., et al. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.007 · Cited by 191
Noël, G., Fontsa, M. L., Garaud, S., De Silva, P., de Wind, A., Van den Eynden, G. G., Salgado, R., Boisson, A., Locy, H., Thomas, N., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci139905 · Cited by 174
Jones, G. W., Hill, D. G., & Jones, S. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00401 · Cited by 169
T1 bladder cancer: current considerations for diagnosis and management
Jordan, B., & Meeks, J. J. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0105-y · Cited by 160
Zander, R., Kasmani, M. Y., Yao, C., Topchyan, P., Shen, J., Zheng, S., Burns, R., Ingram, J. T., Cui, C., Joshi, N. S., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.01.018 · Cited by 155
Goswami, S., Chen, Y., Anandhan, S., Szabo, P. M., Basu, S., Blando, J. M., Liu, W., Zhang, J., Natarajan, S. M., Xiong, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc4220 · Cited by 133
Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study
Vermeulen, S. H., Hanum, N., Grotenhuis, A. J., Castaño-Vinyals, G., van der Heijden, A. G., Aben, K. K., Mysorekar, I. U., & Kiemeney, L. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.601 · Cited by 117
Karam, M. R. A., Oloomi, M., Mahdavi, M., Habibi, M., & Bouzari, S. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.12.059 · Cited by 100
Analysis of bacterial-surface-specific antibodies in body fluids using bacterial flow cytometry
Moor, K., Fadlallah, J., Toska, A., Sterlin, D., Balmer, M. L., Macpherson, A. J., Gorochov, G., Larsen, M., & Slack, E. M. C. (2016) · Nature Protocols · doi:10.1038/nprot.2016.091 · Cited by 99
Marliot, F., Chen, X., Kirilovsky, A., Sbarrato, T., El Sissy, C., Batista, L., Van den Eynde, M., Haicheur-Adjouri, N., Anitei, M.-G., Musina, A.-M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000272 · Cited by 81
Self-citationBriganti, A., Gandaglia, G., Scuderi, S., Andrea Gallina, A., Colombo, R., Fossati, N., Barletta, F. M., Pellegrino, A. A., Nocera, L., Montorsi, F., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.12.019 · Cited by 71
The urinary microbiota: a paradigm shift for bladder disorders?
Brubaker, L. T., & Wolfe, A. J. (2016) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000298 · Cited by 67
Urinary tract infections and reduced risk of bladder cancer in Los Angeles
Jiang, X., Castelao, J. E., Groshen, S. G., Cortessis, V. K., Shibata, D. K., Conti, D. V., Yuan, J.-M., Pike, M. C., & Gago-Domínguez, M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604889 · Cited by 59
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment
Wong, Y. N. S., Joshi, K., Khetrapal, P., Ismail, M., Reading, J. L., Sunderland, M. W., Georgiou, A., Furness, A. J. S., Ben Aissa, A., Ghorani, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20181003 · Cited by 57
Cancer Core Europe: A translational research infrastructure for a European mission on cancer
Eggermont, A. M. M., Apolone, G., Baumann, M. A., Caldas, C., Celis, J. E., Lorenzo, F. D., Ernberg, I. T., Ringborg, U. K., Rowell, J., Tabernero, J. M., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12447 · Cited by 50
Brons, J. K., Vink, S. N., de Vos, M. G. J., Reuter, S., Dobrindt, U., & van Elsas, J. D. (2019) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2019.105799 · Cited by 48
The multiple antibacterial activities of the bladder epithelium
Wu, J., Miao, Y., & Abraham, S. N. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.71 · Cited by 42
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
Recondo, G., Mahjoubi, L., Maillard, A., Loriot, Y., Bigot, L., Facchinetti, F., Bahleda, R., Gazzah, A., Hollebecque, A., Mezquita, L., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00130-7 · Cited by 40
Self-citationSzabados, B. E., Rodríguez‐Vida, A., Durán, I., Crabb, S. J., van der Heijden, M. S., Pous, A. F., Gravis, G., Anido, U., Protheroe, A. S., Ravaud, A., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2020.11.010 · Cited by 34
Self-citationLocal induction of bladder Th1 responses to combat urinary tract infections
Wu, J., Bao, C., Reinhardt, R. L., & Abraham, S. N. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026461118 · Cited by 33
Immunodynamics of explanted human tumors for immuno‐oncology
Dubuisson, A., Fahrner, J., Goubet, A., Terrisse, S. A., Voisin, N., Bayard, C., Lofek, S., Drubay, D., Bredel, D., Mouraud, S., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012850 · Cited by 28
Self-citationWinoker, J. S., Liaw, C. W., Galsky, M. D., Wiklund, P. N., & Mehrazin, R. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.08.009 · Cited by 22
Pfister, C., Gravis, G., Fléchon, A., Chevreau, C., Mahammedi, H., Laguerre, B., Guillot, A., Joly, F., Soulie, M., Allory, Y., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.048 · Cited by 15
Self-citation
Cited by
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances
Zhao, L., Jin, S., Wang, S., Zhang, Z., Wang, X., Chen, Z., Wang, X., Huang, S., Zhang, D., & Wu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01947-5 · Cited by 218
Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes
Yang, Y., Chen, X., Pan, J., Ning, H., Zhang, Y., Bo, Y., Ren, X., Li, J., Qin, S., Wang, D., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.038 · Cited by 208
T follicular helper cells in cancer
Gutiérrez-Melo, N., & Baumjohann, D. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.12.007 · Cited by 209
Derosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.029 · Cited by 198
Self-citation
Metadata
- Authors
- Goubet, A.-G., Lordello, L., Alves Costa Silva, C., Peguillet, I., Gazzano, M., Mbogning-Fonkou, M. D., Thelemaque, C., Lebacle, C., Thibault, C., Audenet, F., Pignot, G., Gravis, G., Helissey, C., Campedel, L., Roupret, M., Xylinas, E., Ouzaid, I., Dubuisson, A., Mazzenga, M., Flament, C., Ly, P., Marty, V., Signolle, N., Sauvat, A., Sbarrato, T., Filahi, M., Davin, C., Haddad, G., Bou Khalil, J., Bleriot, C., Danlos, F.-X., Dunsmore, G., Mulder, K., Silvin, A., Raoult, T., Archambaud, B., Belhechmi, S., Gomperts Boneca, I., Cayet, N., Moya-Nilges, M., Mallet, A., Daillere, R., Rouleau, E., Radulescu, C., Allory, Y., Fieschi, J., Rouanne, M., Ginhoux, F., Le Teuff, G., Derosa, L., Marabelle, A., Van Dorp, J., Van Dijk, N., Van Der Heijden, M. S., Besse, B., Andre, F., Merad, M., Kroemer, G., Scoazec, J.-Y., Zitvogel, L., & Loriot, Y.
- Affiliations
- Inserm (FR)
- 1Gustave Roussy, Villejuif, France.
- 6Urology Department, University Hospital of Bicêtre-Paris Sud-Saclay University, Le Kremlin Bicêtre, Paris, France.
- Université Paris Cité (FR)
- Institut Paoli-Calmettes (FR)
- 10Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France.
- 11Military Hospital Begin, Saint-Mandé, France.
- Sorbonne Université (FR)
- 13GRC 5 Predictive Onco-Uro, Sorbonne University, Department of Urology, AP-HP, Pitie-Salpetriere Hospital, Paris, France.
- Hôpital Bichat-Claude-Bernard (FR)
- 14Department of Urology, Bichat-Claude Bernard Hospital, Paris University, Paris France.
- 18Veracyte, Marseille, France.
- Institut de Recherche pour le Développement (FR)
- 19Aix-Marseille University, IRD, APHM, MEPHI, Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France.
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- 22Institut Pasteur, Université de Paris, CNRS UMR2001, INSERM U1306, Unité de Biologie et Génétique de la paroi bactérienne, Paris, France.
- Institut Pasteur (FR)
- 23Core Facility Ultrastructural BioImaging Core Facility, Institut Pasteur, Paris France.
- 24EverImmune, Gustave Roussy, Villejuif, France.
- 25Department of Medical Biology and Pathology, Cancer Genetics Laboratory, Gustave Roussy, Villejuif, France.
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Agency for Science, Technology and Research (SG)
- 31Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- 32Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- 35The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Goubet, Anne-Gaëlle
- Lordello, Leonardo
- Alves Costa Silva, Carolina
- Peguillet, Isabelle
- Gazzano, Marianne
- Mbogning-Fonkou, Maxime Descartes
- Thelemaque, Cassandra
- Lebacle, Cédric
- Thibault, Constance
- Audenet, François
- Pignot, Géraldine
- Gravis, Gwenaelle
- Helissey, Carole
- Campedel, Luca
- Roupret, Morgan
- Xylinas, Evanguelos
- Ouzaid, Idir
- Dubuisson, Agathe
- Mazzenga, Marine
- Flament, Caroline
- Ly, Pierre
- Marty, Virginie
- Signolle, Nicolas
- Sauvat, Allan
- Sbarrato, Thomas
- Filahi, Mounia
- Davin, Caroline
- Haddad, Gabriel
- Bou Khalil, Jacques
- Bleriot, Camille
- Danlos, François-Xavier
- Dunsmore, Garett
- Mulder, Kevin
- Silvin, Aymeric
- Raoult, Thibault
- Archambaud, Baptiste
- Belhechmi, Shaima
- Gomperts Boneca, Ivo
- Cayet, Nadège
- Moya-Nilges, Maryse
- Mallet, Adeline
- Daillere, Romain
- Rouleau, Etienne
- Radulescu, Camelia
- Allory, Yves
- Fieschi, Jacques
- Rouanne, Mathieu
- Ginhoux, Florent
- Le Teuff, Gwénaël
- Derosa, Lisa
- Marabelle, Aurélien
- Van Dorp, Jeroen
- Van Dijk, Nick
- Van Der Heijden, Michiel S.
- Besse, Benjamin
- Andre, Fabrice
- Merad, Miriam
- Kroemer, Guido
- Scoazec, Jean-Yves
- Zitvogel, Laurence
- Loriot, Yohann
- Venue
- Cancer Discovery
- Published
- 2022-08-05
- Volume
- 12
- Issue
- 10
- Pages
- 2280-2307
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4289936629
- Cited by
- 86
- References
- 85
- Citations by year
- 2026: 18 · 2025: 18 · 2024: 33 · 2023: 16 · 2022: 1
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Funders
- Fondation pour la Recherche Médicale (FDM201806006036)
- RHU5 (ANR-21-RHUS-0017)
- RHU Torino Lumiere (ANR-16-RHUS-0008)
- ANR (19-CE15-0029-01)
- EU-H2020 (825410)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- muscle-invasive bladder cancer, neoadjuvant pembrolizumab, anti-PD-1 therapy, T follicular helper cells, CXCL13, Escherichia coli, tumor-infiltrating immune cells, tertiary lymphoid structures, PD-L1, treatment response biomarkers, progression-free survival
- MeSH terms
- Immune Checkpoint Inhibitors, Urinary Bladder Neoplasms, Escherichia coli, T-Lymphocytes, Helper-Inducer, Humans, Immunoglobulin G, Muscles, Treatment Outcome, Neoadjuvant Therapy, Chemokine CXCL13, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.